Esophageal cancer drugs market

Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

Request Free Sample

Sep 2019
CMI3036
166 Pages
Excel & Pdf
Pharmaceutical

Summary

Esophageal cancer drugs are extensively used in the treatment of esophageal adenocarcinoma, squamous cell carcinoma, and others types. More men are affected by esophageal cancer than women. Esophageal cancer is mostly observed in low-income countries. For instance, according to World Cancer Research Fund (WCRF) International report of 2018, highest rate of esophageal cancer was found to be in Malawi, Mongolia, Kenya, and Bangladesh. Treatments such as chemotherapy, immunotherapy, and targeted drug therapies are available for esophageal cancer. Some drugs are used in combinations and are approved by the Food and Drug Administration (FDA) such as XELIRI combinations of Capecitabine and Irinotecan Hydrochloride.

The global esophageal cancer drugs market size was valued at US$ 765.2 million in 2018 and is expected to witness a CAGR of 8.2% over the forecast period (2019 – 2027).

Global Esophageal Cancer Drugs Market Share (%) Analysis, By Therapy Type, 2018

Source: Coherent Market Insights Analysis (2019)

Increasing research & development and increasing prevalence of achalasia is expected to drive growth of the esophageal cancer drugs market

Increasing research and development and launches of novel products by key players are major factors that are expected to drive growth of the global esophageal cancer drugs market in the near future. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to significantly drive growth of esophageal cancer drugs market size. For instance, in February 2019, researchers at Case Western Reserve University, U.S. found that by blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma (EAC), the most common esophageal malignancy in the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.

Furthermore, the major risk factors that leads to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors are expected to increase demand for esophageal cancer drugs over the forecast period. For instance, according to a study published in National Center for Biotechnology Information in 2017, achalasia patients have 50 times higher risk of incidence of esophageal squamous cell carcinoma than the general population. The overall prevalence of achalasia is 9 to 10 in 100,000 people annually, worldwide.

Esophageal Cancer Drugs Market - Restraints

However, high cost of therapy for the treatment of esophageal cancer is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 per year for the treatment and medications while in 1995, the cost was US$ 54,100 per year.

Moreover, the side effects caused by esophageal cancer drugs are loss of appetite and weight loss, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (deep vein thrombosis), nervous system damage, and heart damage. According to the 2017 report of the American Cancer Society (ACS), side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.

Esophageal Cancer Drugs Market - Regional Insights

On the basis of region, the global esophageal cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global esophageal cancer drugs market during the forecast period, owing to high prevalence of esophageal cancer in this region. For instance, the according to American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.

Asia Pacific is expected to witness rapid growth in the esophageal cancer drugs market during the forecast period, owing to rise in clinical trials conducted in Asian countries for novel drugs to treat esophageal cancer. For instance, National Cancer Center Hospital, Tokyo started a clinical trial in December 2018, which evaluated the comparative study between combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus.

Global Esophageal Cancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Source: Coherent Market Insights Analysis (2019)

Esophageal Cancer Drugs Market - Competitive Landscape

Key players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.

Table of Content

Table of Contents

*Browse 38 market data tables and 27 figures on "Esophageal Cancer Drugs Market” - Global forecast to 2026”

N/A

- Frequently Asked Questions -

What are the growth estimates for esophageal cancer drugs market till 2027?

The global esophageal cancer drugs market is estimated to surpass US$ 1,547.8 Million by 2027

Which are the prominent esophageal cancer drugs market players across the globe?

Major players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.

What are the key factors hampering growth of the esophageal cancer drugs market?

High cost of therapy for the treatment of esophageal canceris one of the major factors that is expected to hamper growth of the market over the forecast period.

What are the key factors driving growth of the esophageal cancer drugs market?

Increasing research & development and increasing prevalence of achalasia are some of the major factors that are expected to propel growth of the market over the forecast period.

What is the compound annual growth rate (CAGR) of the esophageal cancer drugs market for next 8 years?

The global esophageal cancer drugs market is estimated to exhibit a CAGR of 8.2% over the forecast period.

Which region is dominating the esophageal cancer drugs market growth?

Among regions, North Americais expected to hold significant market share in the global esophageal cancer drugs market over forecast period